SeaBeLife

SeaBeLife secures €2 million

This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 — Roscoff, France — SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular necrosis, today announces a pre-Series A funding round worth €2 million ($2.25M).  The financing was led by historical investor…
Place Georges Teissier 29680 ROSCOFF

+33(0)2 98 29 23 48